XML 65 R52.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information - General (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
segment
Jun. 30, 2016
USD ($)
Net product sales, cost of product sales and gross profit by product        
Net product sales $ 444.6 $ 412.6 $ 815.1 $ 781.6
Cost of product sales 18.9 20.0 33.2 20.7
Gross profit 425.7 392.6 $ 781.9 760.9
Segment disclosures        
Number of operating segments | segment     1  
Remodulin        
Net product sales, cost of product sales and gross profit by product        
Net product sales 157.7 158.9 $ 303.5 298.7
Cost of product sales 3.9 3.0 5.9 0.6
Gross profit 153.8 155.9 297.6 298.1
Tyvaso        
Net product sales, cost of product sales and gross profit by product        
Net product sales 104.2 107.0 191.6 209.2
Cost of product sales 2.9 6.3 5.7 7.1
Gross profit 101.3 100.7 185.9 202.1
Adcirca        
Net product sales, cost of product sales and gross profit by product        
Net product sales 120.6 90.9 200.6 163.5
Cost of product sales 6.7 5.2 11.3 9.5
Gross profit 113.9 85.7 189.3 154.0
Orenitram        
Net product sales, cost of product sales and gross profit by product        
Net product sales 46.0 38.0 85.3 78.2
Cost of product sales 4.0 3.1 6.8 2.7
Gross profit 42.0 34.9 78.5 75.5
Unituxin        
Net product sales, cost of product sales and gross profit by product        
Net product sales 16.1 17.8 34.1 32.0
Cost of product sales 1.4 2.4 3.5 0.8
Gross profit $ 14.7 $ 15.4 $ 30.6 $ 31.2